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Abstract
Background: Dengue is today the most significant of arboviral diseases. Novel tools are necessary to effectively
address the problem of dengue. Virus-like particles (VLP) offer a versatile nanoscale platform for developing tools
with potential biomedical applications. From the perspective of a potentially useful dengue-specific tool, the
dengue virus envelope protein domain III (EDIII), endowed with serotype-specificity, host receptor recognition and
the capacity to elicit virus-neutralizing antibodies, is an attractive candidate.
Methods: We have developed a strategy to co-express and co-purify Hepatitis B virus surface (S) antigen in two
forms: independently and as a fusion with EDIII. We characterized these physically and functionally.
Results: The two forms of the S antigen associate into VLPs. The ability of these to display EDIII in a functionally
accessible manner is dependent upon the relative levels of the two forms of the S antigen. Mosaic VLPs containing
the fused and un-fused components in 1:4 ratio displayed maximal functional competence.
Conclusions: VLPs armed with EDIII may be potentially useful in diagnostic, therapeutic and prophylactic applications.
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Background
Currently, dengue represents the most important arboviral
disease that places nearly half the global population at risk
[1]. The mosquito-borne disease is caused by four closely
related, yet antigenically distinct, serotypes of dengue vi-
ruses (DENV-1, -2, -3 and −4) [2]. All four DENVs and
their mosquito vectors are co-prevalent in more than
one hundred tropical/sub-tropical countries. Each of the
DENVs can cause disease ranging from mild dengue
fever to severe dengue hemorrhagic fever and potentially
fatal dengue shock syndrome [3]. Tools for diagnosing,
treating and ultimately preventing dengue are urgently
needed [4]. While increasingly reliable diagnostic tools
are becoming available [4-6], antivirals [4,7,8] and vac-
cines [9,10] for dengue continue to be elusive.
Nanobiotechnology, which seeks to use naturally
occurring as well as engineered nanoscale biomate-
rials to make functional systems, is rapidly emerging
as a platform for the development of novel nanotools
with potential biomedical applications [11-13]. We
are interested in exploring potential applications of
this technology to infectious diseases. We have utilized
Eu3+-doped polystyrene nanoparticles as very sensitive
reporters for detecting Hepatitis B virus [14] and hu-
man immunodeficiency virus [15] infections. We have
also used nanoparticles of biological origin, namely,
virus-like particles (VLPs). Many viral capsid proteins
possess intrinsic ability to self-assemble into VLPs
when expressed in recombinant insect, yeast and mam-
malian host systems [13]. Recently, we have begun ex-
ploring VLP platforms for the display of foreign
antigens [16]. The foreign antigen we focus on is de-
rived from the major DENV structural antigen on the
virion surface, the envelope protein. Multiple antigenic
determinants that are largely serotype-specific map to a
C-terminal ~100 amino acid (aa) region of this protein
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[17]. Further these antigenic determinants tend to elicit
DENV-neutralizing antibodies and coincidentally, this
C-terminal region, which is known as envelope domain
III (EDIII), is also implicated in host receptor recognition
[18]. For these reasons, we believe EDIII offers an attractive
precursor for developing nanoparticle tools that may be
useful in addressing the problem of dengue.
Recombinant Hepatitis B virus surface (S) antigen is
well-documented to self-assemble into 20–22 nm VLPs
[19-21] and is the main component of commercial
Hepatitis B vaccines [22,23]. In this study, we sought
to exploit the S antigen VLP as a carrier for DENV-2
EDIII. To this end we fused EDIII to the amino-terminus
of S to create a fusion antigen, herein referred to as
ES antigen. We used the methylotrophic yeast Pichia
pastoris, which we have found earlier to express S
antigen VLPs to very high levels [20], to express the
ES antigen. We found that for DENV-2 EDIII to be
displayed on the VLP surface in way that made it access-
ible to DENV-2-specific antibody and to the host cell re-
ceptor, it was necessary to co-express the ES fusion
antigen with un-fused S antigen. We describe our strat-
egy to co-express ES and S antigens in P. pastoris, their
co-purification and structural as well as functional
characterization of the resultant mosaic ES,S VLPs.
Results
Strategy to co-express ES fusion antigen gene in the
background of 0–4 copies of S gene
The ES fusion antigen was designed to contain the
DENV-2 EDIII (spanning aa residues 297–400 of the
full-length envelope protein), linked in-frame to the amino-
terminus of the Hepatitis B S antigen through a pentapep-
tide linker (Additional file 1: Figure S1). The ES gene was
placed under the transcriptional control of the P. pastoris
alcohol oxidase 1 (AOX1) promoter. This construct is
designed to express a ~37 kDa ES antigen with the
first 104 and the last 226 aa residues representing, re-
spectively, the DENV-2 EDIII and S fusion partners,
in the absence of any un-fused S antigen. As the ES
antigen by itself did not form VLPs efficiently (see
below), we attempted to co-express varying levels of
un-fused S antigen as well. For this, 1, 2 and 4 copies
of an S gene expression cassette (once again, AOX1
promoter-driven), were inserted at the 5’ end of the
ES expression cassette in a sequential head-to-tail
manner, using an in vitro multimerization strategy de-
scribed previously [19]. The S antigen expression cas-
sette is designed to generate a ~24 kDa protein,
whose aa sequence is identical to the C-terminal 226
aa residues of the ES antigen. A schematic representa-
tion of the basic map of these constructs is depicted
in Figure 1A. Putative VLPs that could arise out of ES
antigen in the absence of any S antigen co-expression
(designated ES,S0), and in the presence of 1, 2 and 4 copies
of the S antigen, designated as ES,S1, ES,S2 and ES,S4, re-
spectively, are shown schematically in Figure 1B.
Creation of P. pastoris clones designed to co-express ES,
S0-4 antigens
The ES gene fusion constructs in the background of 0–4
copies of S gene, described above, were integrated into
P. pastoris using standard methods. Selected transformants
representing each of the constructs were analysed for ES
and S antigen expression upon methanol induction. The
results of a typical experiment analysing the polypeptide
profiles of induced cell lysates are shown in Figure 2A.
Upon induction, a new polypeptide band of ~24 kDa, con-
sistent with the predicted size of the S antigen, is apparent
in all clones harboring the S gene (compare lanes ‘1-4’ with
lane ‘U’). As expected, the clone lacking the S gene did not
express the 24 kDa band (compare lanes ‘U’ with ‘0’). Inter-
estingly, the band intensity of this ~24 kDa polypeptide
seemed to reflect the S gene copy number, being indiscern-
ible in the S gene-lacking clone (lane ‘0’), but maximal in
the clone harbouring 4 copies of the S gene (lane ‘4’). How-
ever, it was difficult to unambiguously detect the presence
of a ~37 kDa protein band, the predicted size of the ES
antigen, in these clones. To confirm if indeed the ES anti-
gen is expressed by these clones we carried out an immu-
noblot assay using an in-house S antigen-specific mAb 5S,
which is expected to recognize both ES as well as S antigen
polypeptides. The data unambiguously revealed the pres-
ence of ~37 kDa ES antigen in the induced lysates of all
four clones (Figure 2B). As expected three of these clones
also co-expressed the ~24 kDa S antigen. Interestingly,
once again, the levels of S antigen manifested a clearly vis-
ible copy number effect. A densitometric analysis of the
relative intensities of the ~24 kDa bands in the 1, 2 and 4
copy clones (Figure 2B, lanes ‘1’, ‘2’ and ‘4’) was found to be
1, 1.8, and 3.9, respectively, closely matching the corre-
sponding S gene copy number for these three clones. This
copy number effect is consistent with our earlier observa-
tion which showed that increasing S gene copy number is
paralleled by a corresponding increase in S mRNA and
protein levels [19]. Further, a densitometric comparison of
ES and S antigen expression levels also showed that
the S/ES ratios were 0.8, 2.4 and 3.7, respectively, for
ES,S1, ES,S2 and ES,S4, This is in good agreement with
the predicted ratios of 1, 2 and 4, for ES,S1, ES,S2 and
ES,S4, respectively. Performing the immunoblot using an
in-house EDIII-specific mAb 24A12 recognized only the
~37 kDa band as expected (Figure 2C). The observed im-
munoreactivities of the ~37 and ~24 kDa polypeptides are
consistent with those of ES and S antigens, respectively.
Collectively, these data confirmed that our panel of P.
pastoris clones co-express ES and S antigen, the latter at
calibrated levels through pre-determined gene copy
Khetarpal et al. Journal of Nanobiotechnology 2013, 11:15 Page 2 of 8
http://www.jnanobiotechnology.com/content/11/1/15
number establishment. It is to be noted that the con-
structs and P. pastoris clones described in this manu-
script are based on DENV-2 EDIII. We have extended
this approach to the EDIIIs of the remaining three DENV
serotypes as well and generated corresponding P. pastoris
clones (data not shown).
The ES,S0-4 antigens are predominantly associated with
the P fraction of induced cell lysates
It has been reported that the S antigen expressed in
yeast associates closely with the cellular membrane
components [21,24,25]. This would predict that the ES
antigen may also manifest this tendency. To investigate
this, we analysed the distribution of the ES antigen be-
tween the soluble and membrane-enriched P fractions of
induced cell lysates. A typical localization experiment is
shown in Figure 3A. Induced total cell lysates (T) were sep-
arated into supernatant (S) and pellet (P) fractions, and all
three samples of each induced clone were evaluated by im-
munoblot assay using mAb 24A12. This revealed that
regardless of S antigen co-expression, the ES antigen was
almost exclusively associated with the P fraction. We next
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Figure 2 Co-expression of ES fusion antigen with 0–4 copies of S antigen in P. pastoris. (A) Methanol-induced P. pastoris clones harboring
the ES fusion gene in the background of 0, 1, 2 and 4 copies of the S gene were lysed and run on SDS-PAGE (lanes are indicated by the S gene
copy number), followed by silver staining. An un-induced sample (of clone ES,S4) was analysed in lane ‘U’. (B) The same samples as in ‘A’ were
transferred onto a nitrocellulose membrane after SDS-PAGE, and subjected to immunoblotting with mAb 5S. (C) Immunoblot analysis similar to
that shown in panel ‘B’, but probed using mAb 24A12. In all three panels, pre-stained protein markers were run in lanes ‘M’; their sizes in kDa are
shown to the left of panel ‘A’. The arrows to the right indicate the positions of the ES fusion (upper) and the S (lower) antigens.
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Figure 1 Strategy to produce DENV-2 EDIII containing VLPs in P. pastoris. (A) Map of pAO815-based P. pastoris-integrative expression vector
carrying HBsAg (S) and EDIII-2-HBsAg (ES) antigen gene expression cassettes in tandem. Each gene is present in an independent expression
cassette with the AOX1 promoter (P) on the 5’ side and the AOX1 transcription terminator (T) on the 3’ side. A family of vectors was created in
which the number (n) of S gene expression cassettes varied from 0–4. Other elements present in the vector include the ampicillin resistance
marker (Amp), the bacterial replication origin (Ori), 3’ terminal sequences of the AOX1 gene (3’AOX1) and the yeast histidinol dehydrogenase
marker gene (HIS4). The dashed arrows point to symbols used to depict the proteins encoded by the ‘S’ (red sphere) and ‘ES’ (red and blue
sphere) genes. Unique sites used for cassette assembly are shown. (B) Schematic representations of the putative VLPs predicted to be generated
from the construct when the ‘S’ antigen copy number is 0 (ES,S0), 1 (ES,S1), 2 (ES,S2) or 4 (ES,S4) per copy of the ‘ES’ fusion antigen.
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sought to quantify the levels of the recombinant antigens
in the P fraction using a sandwich ELISA approach. Anti-
gens were captured using either EDIII-specific or S-specific
mAb and revealed using a second S antigen-specific mAb
conjugate (Additional file 1: Figure S2). This experiment
confirmed the association of both ES and S antigens al-
most exclusively with the P fraction for all clones. In line
with expectation, when recombinant antigens were cap-
tured using mAb specific to S antigen, we observed a
copy number-dependent increase in antigen levels. How-
ever, it is to be noted that this ELISA recognizes both ES
and S antigens. Interestingly, even though all P. pastoris
clones were designed to express ES antigen from a single
copy gene, we found ES levels paralleled the increase in
S antigen gene copy number, when mAb 24A12 was used
for capture. We interpret this data to reflect more effi-
cient capture of ES antigen in the sandwich ELISA as the
levels of co-expressed S antigen increases.
Co-purification of the ES and S antigens from induced
P. pastoris cells
As a prelude to purification, we sought to optimize the
conditions of induction. To this end, methanol concen-
tration and induction duration were varied with respect
to each other, followed by analysis of ES antigen in the P
fractions by immunoblotting and ELISA. Based on these
results (Additional file 1: Figure S3), we carried out in-
duction at 1% methanol for 3 days. As the ES antigen
was predominantly associated with the P fraction, we
decided to adapt a protocol recently developed in our
laboratory that exploits a similar behaviour of the S
antigen for its purification [21]. Thus, the P fraction
from induced cells which served as the starting material
was solubilized in the presence of detergent and urea,
subjected to polyethylene glycol 6000 (PEG 6000) precipi-
tation, tangential flow filtration (TFF) using a 300 kDa cut-
off membrane, and finally chromatography on Phenyl
Sepharose. The peak fractions were pooled and ali-
quots analysed by silver stained SDS-PAGE as shown
in Figure 3B. The data reveal that both the ES and S
antigens expressed by each of the ES,S1-4 clones co-
purified through the multistep purification protocol.
A densitometric scan revealed >95% purity for each.
That the co-purified proteins were indeed ES and S
was confirmed by their identification in a Western
blot analysis using mAbs 5S (Figure 3C) and 24A12
(data not shown). Importantly, both the silver stained
gel and the immunoblot analyses revealed the copy
number effect in S antigen levels. To explore if purifi-
cation could be achieved in the absence of urea, we
used an alternate protocol in which the starting mater-
ial was the soluble fraction obtained from total cell lys-
ate prepared in the presence of 0.6% Tween 20 [25].
This resulted in low yields (data not shown), commen-
surate with the low concentrations in the S fractions
(Additional file 1: Figure S2).
Co-expressed ES and S antigens form VLPs
The demonstration that ES and S antigens could be co-
purified, particularly in a protocol that involved TFF
across a 300 kDa cut-off membrane suggested that the
ES and S antigens are closely associated with each other
and presumably incorporated into higher order structures.
To investigate this further, we analysed a partially purified
preparation (obtained after the TFF step) from the ES,S4
clone on a CsCl density gradient. Fractions were analysed
in ES- and S-specific sandwich ELISAs, referred to above.
This revealed that both ES and S antigens co-sedimented
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Figure 3 Purification of the P. pastoris-expressed ES,S0, ES,S1, ES,S2, and ES,S4, antigens. (A) Localization of the recombinant ES fusion
antigens by Western blot analysis using mAb 24A12. Four ES fusion protein-expressing P. pastoris clones, co-expressing 0, 1, 2 and 4 copies of the
S antigen (indicated by Arabic numerals on the right side of the immunoblot strips) were analysed. Aliquots of P. pastoris cultures were analysed
before (U) and after methanol induction; induced cell extracts were analysed before (T) and after separation into supernatant (S) and pellet (P)
fractions. Pre-stained protein markers were analysed in lanes ‘M’. Their sizes (in kDa) are indicated to the left. (B) Polypeptide profiles of the
recombinant ES,S0 (lane ‘0’), ES,S1 (lane ‘1’), ES,S2 (lane ‘2’), and ES,S4 (lane ‘4’), antigens purified from the ‘P’ fractions of the induced cells (described
in panel ‘A’), visualized by silver staining. (C) Western blot analysis of the purified proteins shown in panel ‘B’, using mAb 5S. Pre-stained protein
markers were run in lane ‘M’. All other lanes are similar to panel ‘B’. For panels ‘B’ and ‘C’, the arrows on the left indicate the positions and sizes
(in kDa) of the protein markers analysed in parallel; the arrows to the right indicate the positions of the ES (upper) and S (lower) antigens.
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together in the bottom one-third of the gradient. An ali-
quot of this fraction containing both ES and S peaks by
electron microscopy revealed the presence of discrete
VLPs (Additional file 1: Figure S4). To answer the ques-
tion if VLP formation occurs when the levels of S antigen
co-expression was lower, aliquots of the pooled peak
phenyl sepharose fractions from each of the four preps
was analysed by electron microscopy (EM) as shown in
Figure 4. This study revealed that the ES,S0 antigen prep-
aration appeared to contain large polydisperse aggregates
without any discrete VLPs. Given that the S antigen
expressed in P. pastoris forms VLPs efficiently [20,21],
this observation may likely indicate that the EDIII fusion
partner in the ES antigen hinders efficient VLP forma-
tion. However, the ability to form VLPs was visibly en-
hanced with increasing levels of co-expressed S antigen.
Thus, the VLPs in the ES,S4 prep manifested the pres-
ence of well-formed VLPs with the highest degree of
homogeneity. Taken together, the purification and EM
data show that the ES,S0 represents aggregates containing
only the ES fusion antigen, whereas the ES,S1, ES,S2 and
ES,S4 represent mosaic VLPs containing progressively in-
creasing proportions of S antigens as well. Further, the
incorporation of ES into VLP is progressively improved
by increasing the relative proportion of S antigen. Similar
VLP formation was evident when purification was done
in the absence of urea, except that yields were extremely
low (data not shown).
S antigen content of VLPs contributes to optimal EDIII
accessibility
Our objective was to display functionally competent
DENV EDIII moieties on the VLP surface. Only then
would such VLPs have potential utility for developing
customized dengue-specific nanotools. To assess surface
accessibility of EDIII, we employed a competitive ELISA
wherein we measured the capacity of these VLPs to
compete with free monomeric EDIII antigen for specific
antigen-binding sites on anti-EDIII antibodies. In the ex-
periment shown in Figure 5A, pre-incubation of the
EDIII-specific mAb 24A12 with S antigen (blue curve)
did not adversely affect its ELISA reactivity towards
yeast-expressed DENV-2 EDIII-2 [26]. On the other
hand, pre-incubation with the ES,S4 VLPs (red curve)
produced a dose-dependent reduction in the capacity of
the mAb towards recombinant EDIII-2, resulting in 50%
reduction at a concentration of 1.4 μg/ml. The ELISA
reactivity of this mAb upon pre-incubation with ES,S0,
ES,S1 and ES,S2 VLPs displayed profiles lying between
these two extremes (data not shown). That all these
VLPs did compete, albeit at different efficiencies, is
clearly a reflection of the surface accessibility of the
VLP-displayed EDIII. It is noteworthy that the relative
proportion of the EDIII moiety is highest in ES,S0 and
the lowest in ES,S4 VLPs. That ES,S4 despite its lowest
EDIII moiety content manifests the highest efficiency in
competing for mAb binding suggests that it provides
for maximal ease of accessibility, and therefore, display
of EDIII moieties, on the VLP surface. It automatically
follows that, if EDIII is displayed on the VLP surface,
it must be able to compete with infectious DENV-2
for host cell receptor-binding. To this end, we exposed
Vero cell monolayers to the different VLP preparations
followed by DENV-2 infection. Successful infection
would be followed by viral replication within the cells.
We followed this using viral NS1 antigen secretion in the
culture supernatant as shown in Figure 5B. The data
showed that the ES,S2 and ES,S4 VLPs were able to po-
tently inhibit NS1 antigen secretion in contrast to the ES,
S0, and ES,S1 VLPs, which were virtually ineffective in
this regard. Once again, the inverse relationship between
relative EDIII content and its functional competence of
the VLPs was reflected in this experiment.
Taken together, the competitive ELISA and virus
binding-blocking experiments support the notion that
mosaic VLPs containing the ES and S antigens in 1:4
ratios display EDIII on the surface in a manner that
is compatible with its optimal interaction with anti-
bodies and the host cell receptors.
Discussion
The magnitude of dengue as a public health problem is
accentuated by the lack of drugs and vaccines [3,4,9].
The emergence of nanotechnology and its increased
A B C D 
Figure 4 Electron microscopic visualization of purified ES,S antigens. The purified ES,S0 (panel ‘A’), ES,S1 (panel ‘B’), ES,S2 (panel ‘C’), and ES,S4
(panel ‘D’), antigens shown in Figure 3B were stained with uranyl acetate and visualized by electron microscopy.
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recent focus on bionanomaterials has opened up new
interdisciplinary avenues exploring novel biomedical ap-
plications [11-13]. Our interest is in exploring this area
with the ultimate goal of developing nanotools that
could help address the dengue problem. In this context,
our interest is in the use of bionanomaterials which have
the intrinsic advantages of biocompatibility and bio-
degradability [12]. In contrast to naturally occurring viral
nanoparticles, which are biohazardous, their genome-
free counterparts, the VLPs, are being increasingly pre-
ferred for developing biomedical nanotools [11-13].
The S antigen of Hepatitis B represents the classic
example of a viral protein which can independently as-
semble into nanoparticles [19-21] and is the basis of a
highly successful VLP vaccine [22,23]. We have sought
to endow DENV specificity to these S VLPs, as a first
step towards developing bionanoparticles with potential
dengue-specific applications. To confer DENV specifi-
city we chose a ~100 aa domain known as EDIII, for
reasons mentioned already, and genetically linked it to
the N-terminus of the S antigen, and expressed it
using P. pastoris. We observed that the resultant ES
antigen did not form VLPs efficiently. Moreover, it did
not display EDIII optimally based on specific assays to
test its functionality. In order to obtain VLPs with
functionally competent EDIII, we developed a strategy
to co-express un-fused S antigen at calibrated levels
using defined S gene copy numbers. The resultant mo-
saic VLPs contain two components, ES antigen and
un-fused S antigen. Both ES and S antigens tend to be
membrane associated, by virtue of the latter’s intrinsic
hydrophobicity [21,24,25]. This necessitated their co-
purification starting from the membrane fraction using
a protocol we developed recently for S antigen purifi-
cation [21]. A noteworthy feature of this purification
scheme is that it eliminates CsCl centrifugation, a bottle-
neck in downstream processing. Based on a variety of cri-
teria including co-purification through 300 kDa cut-off
TFF, CsCl gradient sedimentation analysis, EM and sand-
wich ELISA’s, we found that ES and S antigens associate
together to form mosaic VLPs. Using competitive ELISA
and bind blocking assays, we demonstrated that mosaic
VLPs containing 4 copies of S antigen per copy of the ES
antigen displayed EDIII moiety optimally.
The data have significant implications from the per-
spective of dengue-specific nanoparticulate tools. As
EDIII can induce virus-neutralizing antibodies [26,27],
the repeat-pattern architecture of the mosaic VLP can
potentially augment its vaccine potential. This notion is
backed by the fact that vaccines based on the VLP plat-
form are already available for Hepatitis B and human
papilloma virus infections [13]. Strategies to load VLPs
with drugs and target viral nanoparticles to tumors are
being actively investigated [12]. Thus, if one can envis-
age charging these mosaic VLPs with a drug against den-
gue, these VLPs through their surface displayed EDIII
can be targeted for drug delivery to DENV-susceptible
cells through host receptor recognition. For vaccine and
drug-delivery applications, the non-replicating, infectious
viral genome-free VLPs offer the advantage of in-built
safety. Additionally, as the EDIII is useful in serotype
identification [27], these mosaic VLPs could also serve in
diagnostic serotyping of DENV infections.
Conclusions
This work shows that DENV EDIII fused to the S anti-
gen, co-expressed with un-fused S antigen forms mosaic
VLPs. VLPs containing the fused and un-fused compo-
nents in 1:4 ratio displayed EDIII optimally. These EDIII-
displaying VLPs have potential vaccine, drug-delivery
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Figure 5 Functional characterization of the ES,S VLPs. (A) Competitive ELISA analysis. Anti-EDIII mAb was pre-incubated either with S (blue curve) or
ES,S4 (red curve) antigen VLPs, followed by titration of residual mAb reactivity on yeast-expressed EDIII-2 antigen-coated ELISA plates. (B) Binding blocking
analysis. Vero cells were pre-incubated with S (curve ‘c’), ES,S0 (curve ‘a’), ES,S2 (curve ‘d’) and ES,S4 (curve ‘e’) VLPs and then infected with DENV-2. Control
DENV-2 infection in the absence of any VLP pre-incubation (curve ‘b’) and mock-infections (dashed curve) were carried out in parallel. The progress of
infection was monitored over a week by measuring the release of NS1 antigen in the culture supernatant. Experiments in both panels A and B were
repeated twice; results of one representative experiment each are shown.
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and diagnostic applications. As these VLPs can be pro-
duced in P. pastoris, which is capable of high productivity
in simple media, they can be expected to be inexpensive,
a significant advantage for resource-poor regions where
dengue is endemic. Finally, the approach developed here
could serve as the basis for a common bionanoparticle
platform for other infections as well.
Methods
The genes ES (1 kb) and S (0.7 kb), codon-optimized for
P. pastoris expression were synthesized by Geneart AG
(Regensburg, Germany). DENV-2 (NGC strain) stock
was from previously reported work [28]. DENV-2 EDIII-
specific monoclonal antibody (mAb) 24A12 [26] and S
antigen-specific mAb 5S [21] were in-house reagents.
A panel of four ES (1 copy) expression vectors, co-
expressing 0, 1, 2 and 4 copies of the S antigen was
created using a head-to-tail in vitro multimerization
method [19]. The ES gene was cloned into the unique
Eco RI site of pAO815 to generate the expression plasmid
pAO-ES,S0. To provide for co-expression of S antigen, 1,
2 and 4 copies of an S gene expression cassette were
inserted sequentially to generate pAO-ES,S1, pAO-ES,S2
and pAO-ES,S4, respectively. Each of the four constructs
above was integrated into the genome of P. pastoris
(GS115) as described before [19].
Typically, yeast cultures were grown at 30°C to log phase
in buffered glycerol-containing medium (BMGY) and
switched to buffered 1% methanol-containing medium
(BMMY) for induction for 72 hours. Total (T) lysates for
analytical experiments were prepared from methanol-
induced cells using glass beads in a detergent-containing
buffer as described [21]. A portion of the total lysate was
separated by centrifugation into S- and the membrane-
enriched P-fractions. Suitable dilutions of T, S and P (urea-
solubilized) fractions in urea-free buffer were used for
sandwich ELISA and immunoblotting experiments.
For purification, we followed a method reported re-
cently for P. pastoris-expressed S antigen purification
starting from the membrane fraction [21] with some
modifications as follows. Induced biomass (100 grams
wet weight) was lysed with glass beads (5 cycles) in a
Dyno-mill (WAB, Muttenz, Switzerland) and centrifuged
to separate out the membrane-enriched P fraction,
which was solubilized in a buffer containing 4 M urea
and 2% Tween 20. The solubilized P fraction was clari-
fied and subjected to 5% PEG 6000 precipitation over-
night. The post PEG supernatant was clarified by
centrifugation and 0.45 μ filtration and subjected to TFF
across a 300 kDa membrane using 12 L of TFF buffer
with step-wise reduction in urea (4 M to 0 M). The TFF
retentate was chromatographed on Phenyl 600 M
Toyopearl resin (Tosoh Bioscience, Stuttgart, Germany).
Bound proteins were eluted using a 0-8 M urea step
gradient (with 2 M increase at each step lasting 5 bed
volumes) in 20 mM sodium bicarbonate buffer (pH 9.6).
Column fractions were analysed by SDS-PAGE, purified
peak fractions pooled, and dialyzed against 1× PBS. In
some instances, we also carried out purification from the
S fraction in the absence of urea as described [25].
Proteins were characterized by ELISA, immunoblot-
ting, CsCl gradient centrifugation and EM. ES protein
was detected by sandwich ELISA using two formats. In
one case, DENV-2 EDIII-specific mAb 24A12 was used
for antigen capture, followed by revealing it with an S
antigen-specific mAb-enzyme conjugate. In the second
case, both capture and reveal mAbs were S antigen-
specific (from Hepanostika Ultra kit, Biomerieux, Marcy
L’Etoile, France). Immunoblot analyses were performed
essentially as reported earlier [16,21] using either mAb
24A12 or 5S mAb. Densitometric analysis of the result-
ant blots was performed using freely available image ana-
lysis software from NIH (ImageJ software). CsCl gradient
fractionation was performed as described previously [19].
The presence of VLPs in the purified preparations was vi-
sualized by EM as before [16].
The functional status of EDIII moiety on the VLPs was
assessed by its ability to (i) compete for binding to a spe-
cific mAb and (ii) inhibit DENV-2 binding to host cell sur-
face receptors. Competitive ELISA was done essentially as
reported [16] using mAb 24A12. Binding blocking assay
was performed using Vero cells (American Type Culture
Collection, Virginia, USA). Briefly, cells were pre-exposed
separately to each of the VLP preparations for 1 hour
followed by infection with DENV-2. Culture supernatants
were sampled at daily intervals for release of viral NS1
antigen using Dengue NS1 Platelia kit (BioRad Inc., USA)
as per the manufacturer’s directions [29].
Additional file
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